关键数据
1.030今开
1.100最高
6.85K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.05%换手率
1.050昨收
0.980最低
7.21K成交额
亏损市盈率静
5.81市净率
0.00%股息率 TTM
-400.98%ROA
1.80052周最高
2.85量比
-7.95M净利润
14.88M总股本
-0.8581每股收益TTM
0.51Beta
-950.12%ROE
0.75052周最低
11.43%振幅
100.00%毛利率
15.62M总市值
1.67回报/风险
4.32%风险率

即将为您带来更多新闻,敬请期待。。。
BioCardia Inc评分
-0.06与上次评分对比预测8.00
财务诊断6.59
技术分析4.93
公司估值6.15
机构认同度3.00
风险评估3.20
分析师评级
买入评级
15.500目标均价
+1224.79%涨幅空间
BioCardia Inc 最新财报电话会记录
BioCardia (BCDA) 2026财年第二季度业绩电话会:CardiAMP日本申报及FDA进展
BioCardia的2026财年第二季度业绩电话会议涵盖了CardiAMP在日本的申报进展、CardiAMP和Helix的FDA监管途径、净亏损收窄以及可支持至2027年的现金储备。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
BioCardia Inc 简介
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
行业生物技术与医疗研究
公司代码BCDA
员工数量17
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Lincoln Alternative Strategies LLC | 7.31% |
|---|
| Satterfield (Thomas A Jr) | 6.73% |
|---|
| Stertzer (Simon H) | 5.99% |
|---|
| Blank (Andrew Scott) | 5.84% |
|---|
| 股东类型 | 占比 |
|---|
| Individual Investor | 23.26% |
|---|
| Corporation | 7.85% |
|---|
| Investment Advisor | 5.18% |
|---|
| Hedge Fund | 0.99% |
|---|
常见问题
BioCardia Inc(BCDA)的当前股价是多少?
BioCardia Inc(BCDA)的当前股价是 1.05。
BioCardia Inc股票的52周最高点是多少?
BioCardia Inc股票的52周最高点是1.80。
BioCardia Inc股票的52周最低点是多少?
BioCardia Inc股票的52周最低点是0.75。
现在BioCardia Inc(BCDA)的股票是买入、持有还是卖出?
根据分析师评级,BioCardia Inc(BCDA)的总体评级为买入,目标价格为15.50。
BioCardia Inc(BCDA)股票的每股收益(EPS TTM)是多少
BioCardia Inc(BCDA)股票的每股收益(EPS TTM)是-0.86。